Loading…
Employees: 793
Size Beijing Konruns Pharmaceutical (603590.SS) is a China Consumer Staples company (Drugstore Chains) with a market value of $617M, the 3360th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥25.65 on 6 Nov 2026.
Performance Over six months the shares fell 27.5%, against -2.0% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 15 in its peer set.
Growth Revenue grew 4.5% over the last twelve months (peer median +7.5%); the operating margin is 19.9% (peer median 3.8%).
Valuation It trades at 21.0× forward earnings against a peer median of 13.7× (2nd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points below its cost of capital (7.1% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥917M | CN¥909M | CN¥819M | CN¥914M | CN¥860M |
| Revenue growth | — | +11% | -10% | +6% | — |
| Gross profit | CN¥798M | CN¥795M | CN¥712M | CN¥787M | CN¥708M |
| EBITDA | CN¥223M | CN¥216M | CN¥154M | CN¥172M | CN¥158M |
| Net income | CN¥171M | CN¥166M | CN¥42.2M | CN¥150M | CN¥101M |
| Free cash flow | CN¥103M | CN¥83.4M | CN¥88.1M | CN¥113M | CN¥31.8M |
| Capital expenditure | CN¥52.0M | CN¥53.4M | CN¥104M | CN¥101M | CN¥96.3M |
| Total debt | CN¥377M | CN¥333M | CN¥246M | CN¥192M | CN¥12.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603590.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.8% | +0.9% | 2nd lowest of 15 |
| 6-month return | -27.5% | -2.0% | 5th lowest of 15 |
| Distance from 52-week high | -49.5% | -34.9% | 3rd lowest of 15 |
| Revenue growth (TTM) | +4.5% | +7.5% | 7th lowest of 15 |
| Operating margin | 19.9% | 3.8% | highest of 15 |
| Forward P/E | 21.0× | 13.7× | 2nd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 11.6% | -6.3% | 3rd most demanding of 13 |
| Growth delivered (Del g) | +2.7% | +11.1% | 2nd lowest of 13 |
| Hurdle (Req g minus delivered) | +8.9 pp | -20.1 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | -2.9 pp | +2.7 pp | 3rd lowest of 15 |
| EV / EBITDA | 17.3× | 5.7× | most expensive of 6 |
| Net debt / EBITDA | -2.4× | 1.0× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Konruns Pharmaceutical 603590.SS | China | $617M | -28% | +4% | 20% | 21.0× | 11.6% | +2.7% |
| Cawachi 2664.T | Japan | $577M | +37% | -1% | 2% | n/a | -5.8% | 0.0% |
| Qol 3034.T | Japan | $567M | +38% | +7% | 6% | 11.3× | -16.2% | +12.4% |
| Luyan Pharma 002788.SZ | China | $555M | -30% | +3% | 3% | n/a | 0.1% | +6.5% |
| Genky DrugStores 9267.T | Japan | $723M | +3% | +8% | 5% | 13.7× | n/a | n/a |
| MedPlus Health Services MEDPLUS.NS | India | $769M | -31% | +21% | 4% | 35.1× | 18.5% | +17.6% |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $829M | -35% | +15% | 8% | n/a | -6.0% | +23.3% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $872M | +9% | +9% | 2% | n/a | 4.0% | +17.4% |
| Landfar Bio-medicine 000504.SZ | China | $395M | -16% | +497% | -2% | n/a | n/a | n/a |
| Yixintang Pharmaceutical 002727.SZ | China | $1.18B | +6% | -2% | 3% | 16.9× | -15.9% | +6.5% |
| Shanghai No. 1 Pharmacy 600833.SS | China | $314M | -24% | +1% | -1% | n/a | 20.4% | +6.1% |
| Ain 9627.T | Japan | $1.23B | -2% | +42% | 4% | 13.4× | -6.5% | +16.9% |
| JZJ Chain Drugstore Corporation 605266.SS | China | $307M | -34% | -5% | 0% | 6.5× | -9.6% | +14.8% |
| Create SD 3148.T | Japan | $1.30B | -2% | +9% | 5% | n/a | -11.5% | +8.0% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.69B | +7% | +3% | 5% | 16.3× | -10.9% | +9.7% |